| Date | Title | Description |
| 15.10.2025 | Arthrosi Secures $153 Million to Accelerate Gout Treatment | Arthrosi Therapeutics recently closed a significant $153 million Series E funding round. This vital capital directly supports late-stage clinical development of pozdeutinurad, a promising next-generation URAT1 inhibitor. The San Diego-based... |
| 14.10.2025 | Arthrosi: $153 Million Series E Raised For Developing Gout Treatments | Arthrosi Therapeutics has closed a $153 million Series E funding round. This late-stage biotechnology company is focused on developing a next-generation URAT1 inhibitor, which has the potential to be a best-in-class treatment for patients s... |
| 08.10.2025 | Arthrosi Raises $153M in Series E Funding | Arthrosi, a San Diego, CA-based late-stage biotechnology company developing URAT1 inhibitors, raised $153M in Series E funding.
The round was led by Prime Eight Capital Limited and with participation from CR Biotech, HighLight Capital, HM V... |
| 17.09.2025 | RobStride builds the joints that keep China’s robots moving, and a thriving industry around them | RobStride Dynamics, founded in November 2023, is carving out a niche in integrated joint modules. In less than two years, it has supplied nearly half of embodied intelligence companies in China.
The company is led by Wang Bo, an automation ... |
| 10.07.2025 | HighLight Capital joins global investors in backing NUCLIDIUM | - |
| 28.05.2025 | To develop novel therapies for cardiomyopathy, Nuevocor raised $45 M Series B funding | The Singapore-based IND-stage biotechnology startup Nuevocor, which is working to find treatments for cardiomyopathies caused by aberrant mechanobiology, has successfully closed a $45 million Series B funding round.
Nuevocor said in a state... |
| 01.04.2025 | Aramco's Prosperity7 leads $73m financing in China's Spirit AI | Prosperity7 Ventures, a venture capital (VC) fund of Saudi oil giant Aramco, has led a Series Pre-A funding round of 528 million yuan ($72.8 million) in China’s Spirit AI amid a frenzy of early-stage financing in embodied intelligence.
Spir... |
| 24.02.2025 | Healthcare focus drives HighLight Capital’s exits amid market downturn | At a time when most fund managers are grappling with a liquidity crunch, Shanghai-based HighLight Capital managed to score several exits and return capital to its investors last year. |
| 03.09.2024 | The Rise of Private Credit: SeaTown's Bold Move in Asia | In the ever-evolving landscape of finance, private credit is emerging as a formidable player. SeaTown Holdings International, a subsidiary of Temasek, has just closed its second private credit fund, SeaTown Private Credit Fund II (PCF II), ... |
| 29.08.2024 | Viva Biotech Announces Its 2024 Interim Results: Significant Improvement in Net Profit Growth and Ongoing Optimization of Emerging Technology Platforms | Results Highlights for Interim Results ended 30 June 2024
Revenue reached RMB981.8 million
Gross profit amounted to RMB339.1 million
Net profit grew by 956.0 YoY to RMB144.2 million
Adjusted non-IFRS net profit reached RMB168.2 million, inc... |